Barry Kappel

Barry Kappel has a diverse work experience that spans over two decades. Barry is currently the Founder, President, and CEO of Sapience Therapeutics, Inc, a biotechnology company focused on discovering and developing peptide-based therapeutics for previously 'undruggable' targets in high mortality cancers. In this role, they oversee the development of drug candidates that target protein-protein interactions responsible for cancer growth and immune response suppression against tumors. Before founding Sapience Therapeutics, Barry was an Executive in Residence at Columbia Technology Ventures, where they facilitated the transfer of research innovations from Columbia University's lab to the market and supported startup efforts. Prior to that, they held the position of Senior Vice President of Business Development at ContraFect Corp, where they played a key role in business development strategies. Barry also has experience in the consulting and finance sectors, having worked as a Senior Consultant at Easton Associates and as an MBA Intern at Bear Stearns. Barry started their career at Memorial Sloan-Kettering Cancer Center, first as a Senior Research Technician and later as a Graduate Research Associate. Overall, Barry's work experience reflects their expertise in the biotechnology industry and their drive for innovation and commercialization of research advancements.

Barry Kappel has a strong academic background with a focus on science and business. Barry started their education at Emory University from 1994 to 1998, where they obtained a Bachelor of Arts degree in Chemistry. Following this, they pursued a higher level of education at the Cornell Johnson Graduate School of Management. From 2001 to 2006, they completed a Ph.D. program in Immunology and Pharmacology. Later, in 2006 and 2007, they attended the same institution to pursue a Master of Business Administration (MBA) degree.